Oculis Holding AG (NASDAQ:OCS – Get Free Report)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $15.81, but opened at $16.49. Oculis shares last traded at $16.30, with a volume of 2,449 shares changing hands.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Oculis in a research note on Wednesday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $29.20.
Oculis Stock Performance
Oculis (NASDAQ:OCS – Get Free Report) last posted its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). The firm had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.28 million. Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. On average, equities research analysts forecast that Oculis Holding AG will post -2.19 earnings per share for the current fiscal year.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
See Also
- Five stocks we like better than Oculis
- How to Most Effectively Use the MarketBeat Earnings Screener
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Invest in the Best Canadian StocksĀ
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.